Emerald raises €1.66M to scale UK preventive healthcare platform
What's the deal? London-based Emerald has raised €1.66 million (£1.4 million) in an early-stage round to scale its preventive healthcare platform. The round included an €832,200 grant from Innovate UK — the company's second award from the body — plus matching venture capital from existing backers and new investors Sequel and Highgoal.
What's the endgame? Founded in 2024, Emerald combines in-clinic laboratory screening with a digital platform that pulls together results, wearable data, and health history in one place. Every member is paired with a GP who can diagnose, prescribe, and refer into private and NHS care.
The numbers: The round lifts Emerald's total funding to €3.44 million (£2.9 million) at an increased valuation. Since the start of 2026, the company says its member base has grown tenfold and it has processed more than 100,000 laboratory tests, with repeat screening showing improved cholesterol levels for two out of three users.
Why now? Chief executive officer Alexander Badalyan ties the model to government priorities, arguing the NHS cannot deliver preventive care alone. "Government efforts must be matched with innovative solutions that are able to have widespread reach," he said. The company has signed partnerships with PluxeeDealroom has a profile for this one. Try Dealroom →, Epassi, and Yonder to offer its services through employee benefits schemes.
The signal: It is a modest round in a crowded, capital-intensive category. UK rival StrideDealroom has a profile for this one. Try Dealroom → raised £4.6 million in October for a similar diagnostics-led membership, Berlin's Circle HealthDealroom has a profile for this one. Try Dealroom → raised €9 million in February, and better-funded players like Neko Health have raised far more — leaving Emerald to prove that early traction can convert into durable adoption and clinical value.
Read more: EU-Startups, Tech Funding News
Image credit: Generated with Gemini
